Fcgamma-receptor-independent controlled activation of CD40 canonical signaling by novel therpeutic antibodies for cancer therapy
C. Reitinger, K. Beckmann, A. Carle, E. Bluemle, N. Jurkschat, C. Paulmann, S. Prassl, L. Kazandijan, F. Nimmerjahn, S. Fischer
Novel Fc-silenced anti-CD40 antibodies activate antigen-presenting cells and humanized mice without Fcγ-receptor dependence, showing efficacy and reduced toxicity compared to existing therapies.
bioRxiv · Jan 16, 2023 · PreprintImmunology